New Computational Tools Developed by Mount Sinai Scientists Yield Superior Genome Analysis Results
Scientists from the Icahn School of Medicine at Mount Sinai have developed and publicly released new data analysis software that could help genomics researchers identify genetic drivers of disease with greater efficiency and accuracy. These tools were published yesterday in PLoS Computational Biology and on November 25th in Scientific Reports, a Nature publication.
MEGENA (for Multiscale Embedded Gene Co-expression Network Analysis) projects gene expression data onto a three dimensional sphere, allowing scientists to study hierarchical organization patterns in complex networks that are characteristic of diseases such as cancer, obesity, and Alzheimer’s. Tested on data from The Cancer Genome Atlas (TCGA), MEGENA identified novel regulatory targets in breast and lung cancers, outperforming other co-expression analysis methods.
The second tool, SuperExactTest, establishes the very first theoretical framework for assessing the statistical significance of multi-set intersections and enables users to compare very large sets of data, such as gene sets produced from genome-wide association studies (GWAS) and differential expression analysis. Scientists ran SuperExactTest on existing TCGA and GWAS data, identifying a core set of cancer genes and detecting related patterns among complex diseases. Both tools come from the Multiscale Network Modeling Laboratory led by Bin Zhang, PhD, Associate Professor in the Department of Genetics and Genomic Sciences.
“These tools fill important and unmet needs in genomics,” said Dr. Zhang, the senior author of the two papers. “MEGENA will help scientists flesh out novel pathways and key targets in complex diseases, while SuperExactTest will provide a clearer understanding of the genome by comparing a large number of gene signatures.”
“Our team is dedicated to crafting high-performance analysis tools and to sharing those resources with the broader genomics community to help us all generate the best possible results,” said Eric Schadt, PhD, the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai, and Founding Director of the Icahn Institute for Genomics and Multiscale Biology. “These new tools demonstrate thoughtful and creative solutions to computational challenges faced by scientists around the world, and I look forward to seeing what the community will accomplish with them.”
MEGENA and SuperExactTest are available as R packages at Dr. Zhang’s website (http://research.mssm.edu/multiscalenetwork/Resources.html) and CRAN (the Comprehensive R Archive Network), a repository of open-source software (https://cran.r-project.org/).
Papers cited:
Won-Min Song and Bin Zhang. Multiscale Embedded Gene Co-expression Network Analysis. PLoS Computational Biology 11(11): e1004574. doi:10.1371/journal.pcbi.1004574 (http://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004574)
Minghui Wang, Yongzhong Zhao, and Bin Zhang. Efficient Test and Visualization of Multi-Set Intersections. Scientific Reports 5:16923. doi: 10.1038/srep16923 (http://www.nature.com/articles/srep16923)
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.